A study in Chinese girls with early puberty showed that adding growth hormone to the drug triptorelin helped them grow taller and gain more weight, slowed down their bone age, lowered sex hormone levels, and reduced ovarian and uterine size, without serious side effects. This was a pediatric setting, so it doesn’t directly translate to adult self‑experimentation for longevity or performance.

<b>Aims/Background</b> Triptorelin effectively delays bone age progression in children with precocious puberty but may suppress pituitary growth hormone response, affecting growth hormone-binding protein secretion and overall growth rate. This study aimed to evaluate the efficacy and safety of triptorelin alone versus in combination with recombinant human growth hormone (rhGH) in treating girls with precocious puberty. <b>Methods</b> This retrospective study examined 82 girls with precocious puberty treated at The First People's Hospital of Tongxiang from January 2021 to June 2023. Patients treated with triptorelin alone were assigned to the control group (n = 42), while those treated with triptorelin combined with rhGH formed the study group (n = 40). Both groups received continuous treatment for one year. Outcomes, including efficacy and safety, were compared between the groups. <b>Results</b> Following treatment, height and body mass in the study group were significantly higher than those in the control group (<i>t</i> = 2.126, <i>p</i> = 0.037; <i>t</i> = 2.419, <i>p</i> = 0.018). The bone age/chronological age (BA/CA) ratio in the study group was significantly lower than that in the control group (<i>t</i> = 2.185, <i>p</i> = 0.032). Levels of estradiol (E₂), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) in the study group were also significantly reduced compared to the control group (<i>t</i> = 2.208, <i>p</i> = 0.030; <i>t</i> = 4.492, <i>p</i> &lt; 0.001; <i>t</i> = 2.952, <i>p</i> = 0.004). Furthermore, left and right ovarian volumes and uterine volume were significantly lower in the study group than those in the control group (<i>t</i> = 2.740, <i>p</i> = 0.008; <i>t</i> = 2.936, <i>p</i> = 0.004; <i>t</i> = 2.520, <i>p</i> = 0.014). After one year, the effective treatment rate in the study group was higher than that in the control group (97.50% vs 80.95%, <i>p</i> &lt; 0.05). No serious adverse reactions were observed in either group during the treatment period. <b>Conclusion</b> The combination of triptorelin and rhGH demonstrates a clear therapeutic in girls with precocious puberty, which effectively delays bone age growth, regulates sex hormone levels, and reduces ovarian and uterine volumes without severe adverse effects.